6-(4-fluoro-phenyl)-4-methyl-2H-pyridazin-3-one | 68612-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(4-fluoro-phenyl)-4-methyl-2H-pyridazin-3-one
• 英文别名: 3-(4-fluorophenyl)-5-methyl-1H-pyridazin-6-one
• CAS: 68612-32-8
• 化学式: C₁₁H₉FN₂O
• 分子量: 204.204
• InChiKey: CRZHDFBWSPGOGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(4-fluoro-phenyl)-4-methyl-2H-pyridazin-3-one 在 三氯氧磷 作用下， 生成 3-chloro-6-(4-fluorophenyl)-4-methylpyridazine
  参考文献：
  名称：

  3-Aminopyridazine derivatives with atypical antidepressant, serotonergic and dopaminergic activities

  摘要：

  Minaprine [3-[(beta-morpholinoethyl)amino]-4-methyl-6-phenylpyridazine dihydrochloride] is active in most animal models of depression and exhibits in vivo a dual dopaminomimetic and serotoninomimetic activity profile. In an attempt to dissociate these two effects and to characterize the responsible structural requirements, a series of 47 diversely substituted analogues of minaprine were synthesized and tested for their potential antidepressant, serotonergic, and dopaminergic activities. The structure-activity relationships show that dopaminergic and serotonergic activities can be dissociated. Serotonergic activity appears to be correlated mainly with the substituent in the 4-position of the pyridazine ring whereas the dopaminergic activity appears to be dependent on the presence, or in the formation, of a para-hydroxylated aryl ring in the 6-position of the pyridazine ring.

  DOI：

  10.1021/jm00123a004
• 作为产物：
  描述：

  衣康酸酐 在 三氯化铝 、 sodium acetate 、 potassium carbonate 、 一水合肼 作用下， 以 甲醇 、 丙酮 为溶剂， 生成 6-(4-fluoro-phenyl)-4-methyl-2H-pyridazin-3-one
  参考文献：
  名称：

  Siddiqui, Anees A.; Wani, Sachin M., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2004, vol. 43, # 7, p. 1574 - 1579

  摘要：

  DOI：

文献信息

• THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES
  申请人：Lavoie Edmond J.

  公开号：US20150232454A1

  公开（公告）日：2015-08-20

  The invention provides compounds of formula (I): and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

  本发明提供公式(I)的化合物，以及其盐和前药，其中R4、X1和X2具有规范中定义的任何含义，以及包含该化合物或盐的药物组合物和在治疗中使用它们的方法。这些化合物具有有用的抗病毒性能。
• Rohr, Markus; Toussaint, Dominique; Chayer, Said, Heterocycles, 1996, vol. 43, # 7, p. 1459 - 1464
  作者：Rohr, Markus、Toussaint, Dominique、Chayer, Said、Mann, Andre、Suffert, Jean、Wermuth, Camille-Georges

  DOI：——

  日期：——
• WERMUTH, CAMILLE-GEORGES;SCHLEWER, GILBERT;BOURGUIGNON, JEAN-JACQUES;MAGH+, J. MED. CHEM., 32,(1989) N, C. 528-537
  作者：WERMUTH, CAMILLE-GEORGES、SCHLEWER, GILBERT、BOURGUIGNON, JEAN-JACQUES、MAGH+

  DOI：——

  日期：——
• ALBRIGHT J. D.; MCEVOY F. J.; MORAN D. B., J. HETEROCYCL. CHEM., 1978, 15, NO 6, 881-892
  作者：ALBRIGHT J. D.、 MCEVOY F. J.、 MORAN D. B.

  DOI：——

  日期：——
• US9573938B2
  申请人：——

  公开号：US9573938B2

  公开（公告）日：2017-02-21